ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0061

Discovery of a RIPK2 Scaffolding Inhibitor for the Treatment of Joint Autoimmune Diseases

Marta Wlodarska1, Chad Van Huis2, Florian Hoss3, Rosana Meyer1, Xiaokang Lu2, Dominik Koelmel2, Brian Sanchez2, Chuck Lesch2, Alissa Telling2, Martin Minns1, Nneka Mbah2, Isabelle Lacan1, Robert Aversa1, Charles Lesburg1, Carmen Yu2, Stephen Soisson1, Natalie Dales1, Darryl Patrick1, Anthony Opipari2, Shifeng Pan4 and Luigi Franchi2, 1Odyssey Therapeutics, Boston, MA, 2Odyssey Therapeutics, Ann Arbor, MI, 3Odyssey Therapeutics, Frankfurt, Germany, 4Odyssey Therapeutics, San Diego, CA

Meeting: ACR Convergence 2023

Keywords: autoimmune diseases, cytokines, Inflammation, Innate Immunity Rheumatic Disease, Monocytes/macrophages

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0040–0064) Innate Immunity Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Receptor interacting protein kinase 2 (RIPK2) is a key signaling node for inflammation caused by peptidoglycan (PGN). In the intestine, RIPK2 integrates signaling originating from the microbiota and amplifies pro-inflammatory responses. Hence, blocking RIPK2 is an attractive strategy to treat inflammatory bowel disease. Since peptidoglycan is present in the serum and joints in patients with rheumatic diseases and is thought to drive sterile inflammation, RIPK2 inhibitors may also be a novel approach to treat rheumatoid arthritis, osteoarthritis, and spondyloarthritis. While the kinase function of RIPK2 is dispensable for downstream signaling, its ability to recruit and activate the E3 ubiquitin ligase, XIAP, is critical for RIPK2 ubiquitination and signal transduction. On this basis, we developed a RIPK2 scaffolding inhibitor that binds to RIPK2, prevents interaction with XIAP, and blocks proinflammatory responses in vitro and in vivo.

Methods: Direct inhibition of RIPK2 scaffolding with XIAP was demonstrated using surface plasmon resonance and a cellular nanoBRET assay. Inhibitory activity was evaluated by NF-kB dependent gene expression in NOD1 and NOD2 reporter cell lines and cytokine production in primary human cells stimulated with PGN fragments or Toll like receptor (TLR) ligands. Potency and selectivity was compared to GSK-559, a RIPK2 kinase inhibitor, and efficacy of the Odyssey RIPK2 scaffolding inhibitor in vivo was evaluated in a PGN-challenge mouse model.

Results: RIPK2 scaffolding inhibitor blocks the binding of recombinant XIAP with RIPK2 in vitro and in cells. RIPK2 scaffolding inhibitor blocks MAPK pathway activation, NF-kB activation, and cytokine production (e.g., TNF, IL-23, and TL1A) in human monocytes and macrophages stimulated with PGN fragments, but not TLR ligands. We observed a synergistic cytokine response in human monocytes stimulated by both NOD1/2 and TLR ligands. This synergistic response is blocked by treatment with a scaffolding inhibitor, but not a RIPK2 kinase inhibitor. Oral administration of the RIPK2 scaffolding inhibitor dose-dependently reduced production of TNF, IL-6, and MCP-1 in response to PGN.

Conclusion: We describe a potent and selective RIPK2 scaffolding inhibitor and demonstrate that blocking scaffolding is necessary to maximally inhibit RIPK2 activation in response to the microbiota. These data show the therapeutic potential of using a RIPK2 scaffolding inhibitor to prevent pathogenic responses to microbiota from which inflammatory intestinal and rheumatic diseases originate.


Disclosures: M. Wlodarska: None; C. Van Huis: None; F. Hoss: None; R. Meyer: None; X. Lu: None; D. Koelmel: None; B. Sanchez: None; C. Lesch: None; A. Telling: None; M. Minns: None; N. Mbah: None; I. Lacan: None; R. Aversa: None; C. Lesburg: None; C. Yu: None; S. Soisson: Merck/MSD, 3, 11; N. Dales: None; D. Patrick: None; A. Opipari: Odyssey Therapeutics, 3; S. Pan: None; L. Franchi: Odyssey Therapeutics, 3, 11.

To cite this abstract in AMA style:

Wlodarska M, Van Huis C, Hoss F, Meyer R, Lu X, Koelmel D, Sanchez B, Lesch C, Telling A, Minns M, Mbah N, Lacan I, Aversa R, Lesburg C, Yu C, Soisson S, Dales N, Patrick D, Opipari A, Pan S, Franchi L. Discovery of a RIPK2 Scaffolding Inhibitor for the Treatment of Joint Autoimmune Diseases [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/discovery-of-a-ripk2-scaffolding-inhibitor-for-the-treatment-of-joint-autoimmune-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/discovery-of-a-ripk2-scaffolding-inhibitor-for-the-treatment-of-joint-autoimmune-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology